Cellular senescence, where cells permanently stop dividing, plays a complex role in liver health. In a recent review article, ...

With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...

Chronic hepatitis C virus (HCV) infection accounts for most cases of hepatocellular carcinoma (HCC) in Japan and is the second major cause in many other countries. Development of HCC takes a ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

Men had a more than twofold greater risk of hepatocellular carcinoma (HCC ... reporting higher HCC risk in men with other chronic liver diseases vs women, our study found a significant association ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Liver cancer is the sixth leading cause of cancer death in the U.S. The most common type of liver cancer in adults is ...

Hepion Pharmaceuticals, Inc. (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developi ...